Who is sponsoring NCT01826877?

NCT01826877 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT01826877?

Interventions in NCT01826877: AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis.

What condition does NCT01826877 study?

NCT01826877 studies Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer.

Is NCT01826877 still recruiting?

NCT01826877 is currently completed. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT01826877

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Completed Phase 1 Last updated 4 August 2021

What this trial tests

Phase 1 trial testing AdGMCAIX-transduced autologous dendritic cells in Clear Cell Renal Cell Carcinoma in 12 participants. Completed in 27 May 2021.

Timeline

14 January 2013

Primary endpoint
3 July 2018

27 May 2021

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	14 January 2013
Primary completion	3 July 2018
Estimated completion	27 May 2021
Sites	1 location across United States

Drugs / interventions tested

AdGMCAIX-transduced autologous dendritic cells — full drug profile →
therapeutic autologous dendritic cells — full drug profile →
laboratory biomarker analysis — full drug profile →

Conditions studied

Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →
Recurrent Renal Cell Cancer — all drugs for Recurrent Renal Cell Cancer →
Stage IV Renal Cell Cancer — all drugs for Stage IV Renal Cell Cancer →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Clear Cell Renal Cell Carcinoma or Recurrent Renal Cell Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.
McDonald PC, Chafe SC, Dedhar S. · · 2016 · cited 108× · PMID 27066484 · DOI 10.3389/fcell.2016.00027
Trial watch: Dendritic cell-based interventions for cancer therapy.
Vacchelli E, Vitale I, Eggermont A, Fridman WH, et al · · 2013 · cited 91× · PMID 24286020 · DOI 10.4161/onci.25771
Toward Normalization of the Tumor Microenvironment for Cancer Therapy.
Zheng J, Gao P. · · 2019 · cited 26× · PMID 31282197 · DOI 10.1177/1534735419862352
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
· 2018 · cited 23× · PMID 30400835 · DOI 10.1186/s40425-018-0422-y
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Combe P, de Guillebon E, Thibault C, Granier C, et al · · 2015 · cited 19× · PMID 26155388 · DOI 10.1080/2162402x.2014.1001236
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Liu KG, Gupta S, Goel S. · · 2017 · cited 18× · PMID 28061473 · DOI 10.18632/oncotarget.14388
Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.
Jahangir M, Yazdani O, Yazdani O, Kahrizi MS, et al · · 2022 · cited 15× · PMID 36510217 · DOI 10.1186/s12935-022-02816-3
Nanomedicine for Combination Urologic Cancer Immunotherapy.
Tian Y, Liu Z, Wang J, Li L, et al · · 2023 · cited 11× · PMID 36839868 · DOI 10.3390/pharmaceutics15020546

Verify or expand the search:

Other recruiting trials for Clear Cell Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01826877 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01826877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing